Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The aim of this work was to assess the effect of long- and short-term incubation with daidzein, the second most abundant soy isoflavone and its metabolite equol on the expression and activity of P-glycoprotein, multidrug resistance-associated proteins 1 and 2 (MRP1 and MRP2) and BCRP in breast cancer cells.
|
29101532 |
2019 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mir-1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53.
|
29697201 |
2018 |
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Motility related protein 1 (MRP-1/CD9) expression: inverse correlation with metastases in breast cancer.
|
7664290 |
1995 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The role of MDM2 and MDM4 in breast cancer development and prevention.
|
28096293 |
2017 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Mechanistically, a high level of p53 protein and a low level of multidrug-resistant protein 1 (MRP1) and breast cancer resistant protein (BCRP) mRNA in KB cells with celecoxib may explain the differential effect of these selective COX-2 inhibitors in KB cells.
|
18202791 |
2008 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Based on our findings, we propose that Mdmx targeting is an attractive strategy for treating BrCas harboring wt p53.
|
26181202 |
2015 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The results from this study suggest, however, that the expression of survivin, survivin-deltaEx3, survivin-2B, bag-1, galectin-3, bax-alpha and MRP-1 mRNAs cannot be considered as prognostic indicators of disease outcome for patients with breast cancer.
|
14607338 |
2003 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
It is unknown, however, whether MDM4 gene alterations play some role in the inherited component of breast cancer susceptibility.
|
18279506 |
2008 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Interaction between p53 mutation and a somatic HDMX biomarker better defines metastatic potential in breast cancer.
|
25649770 |
2015 |
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Recently, a 4-nitrobenzofuroxan derivative, XI-006 (NSC207895) was shown to diminish MDM4 promoter activity in breast cancer cell lines.
|
26095524 |
2015 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genes encoding proteins that have key functions in the DNA damage response, such as p53 and its inhibitors MDM2 and MDMX, are most likely candidates to harbor allelic variants that influence breast cancer susceptibility.
|
30956778 |
2019 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study evaluated the association of a SNP in human MDM4 (C>T) with age of onset of breast cancer in two independent cohorts.
|
19762336 |
2009 |
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization.
|
30814489 |
2019 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The results showed that Que could increase intracellular accumulation of Dox in breast cancer cells through down-regulating the expression of efflux ABC transporters including P-gp, BCRP and MRP1, which can effectively eliminate cancerous cells including breast cancer stem cells (BCSCs), thereby potentiating the anti-tumor effect of Dox.
|
29475141 |
2018 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The authors studied the effects of AN-238 and AN-201 on the expression levels of MDR-1, multidrug resistance related protein (MRP-1), and breast carcinoma resistance protein (BCRP) by real-time polymerase chain reaction.
|
16047355 |
2005 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Expression of LRP Gene in Breast Cancer Patients Correlated with MRP1 as Two Independent Predictive Biomarkers in Breast Cancer
|
30486550 |
2018 |
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
linc00518 expression increased nearly 2 fold and MRP1 level elevated about 2.5 fold in breast cancer tissues as compared to that in adjacent normal tissues.
|
30001527 |
2018 |
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Elevated MRP-1/CD9 expression on tumor cells has been linked to a favorable prognosis in breast cancer, colon cancer, lung cancer, and HNSCC.
|
12966509 |
2003 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our findings proposed that the MDM4 rs1380576 C>G polymorphism was a protective factor for BC risk in our population.
|
29439926 |
2018 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Expression of MDM2 and MDMX occurs in estrogen receptor α-positive (ERα<sup>+</sup>) breast cancer and triple-negative breast cancer (TNBC).
|
30642351 |
2019 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
|
15015586 |
2004 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).
|
23396606 |
2013 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We conclude, MDM4 SNP34091 status to be associated with reduced risk of breast cancer, in particular in individuals carrying the MDM2 SNP309GG genotype, but not to be associated with either lung-, colon- or prostate cancer.
|
26471763 |
2015 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Fresh frozen samples of 45 primary OSCC were investigated for the expression of mdr1 (p-glycoprotein-mediated multi-drug resistance), mrp1 (multi-drug resistance-related protein) and bcrp (breast cancer-related protein), using a reverse transcriptase PCR.
|
15113040 |
2004 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
As a result, the expression of motility related protein-1 (MRP-1/CD9), peripheral myelin protein-22 (PMP-22), and caspase 3 (CASP-3) were down-regulated in M compared to T. We focused especially on MRP-1 and found that the expression status of MRP-1 was significantly inversely associated with stage of disease in 56 cases of breast cancer (P<0.05), and the relapse free survival in 5 years was significantly higher in MRP-1 positive cases than those negative cases (P<0.05).
|
16132579 |
2005 |